Clinical Trials · NCT03914326
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 9,651
- Start date
- Jun 2019
- Locations
- 492 sites, 34 countries
- Primary endpoint
- Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal Stroke